CVS Health Corp vs Kraft Heinz Co — how do they compare? CVS Health Corp trades at $93.68 (market cap $122.36B), while Kraft Heinz Co trades at $24.64 (market cap $29.56B). The key difference: CVS Health Corp is far larger — about 4.1× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (6.42%). Which is the better fit depends on your goals.
| CVS | KHC | |
|---|---|---|
Market Cap | $122.36B | $29.56B |
Sector | Health | Consumer Staples |
52-Week High | $110.60 | $28.06 |
52-Week Low | $64.88 | $21.21 |
Enterprise Value | $184.71B | $45.88B |
Dividend Yield | 2.78% | 6.42% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Kraft Heinz (KHC) trades at $25.32, up 1.44% today, with a bearish technical signal but oversold RSI. The stock shows mixed fundamentals: earnings beat estimates in recent quarters, yet 2025 net income was -$5.85B, reflecting margin pressures. Revenue declined to $24.94B in 2025, while the P/E of 13.04 and P/B of 0.83 suggest undervaluation. Recent news highlights CEO Cahillane's strategy to boost marketing spend for growth, amid institutional selling by firms like Bank of America (Defense World, 2026-08-09).
Outlook remains cautious; the 6% dividend yield attracts income investors, but sustainability is questioned amid profit declines. Risks include persistent inflation and competitive headwinds. Analysts are mostly neutral (57.14% Hold), with a $24 consensus target, implying limited upside. The stock's trajectory hinges on successful execution of turnaround efforts to stabilize earnings.
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →